Clinical Trials Logo

Myelodysplastic Syndrome clinical trials

View clinical trials related to Myelodysplastic Syndrome.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 6

NCT ID: NCT00392353 Active, not recruiting - Clinical trials for Myelodysplastic Syndrome

Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Start date: November 22, 2006
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of vorinostat and azacitidine and to see how well they work in treating patients with myelodysplastic syndromes or acute myeloid leukemia. Vorinostat may stop the growth of cancer or abnormal cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer or abnormal cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving vorinostat together with azacitidine may kill more cancer or abnormal cells.

NCT ID: NCT00057031 Active, not recruiting - Clinical trials for Myelodysplastic Syndrome

Study of High-Dose Pulse Administration DN-101 (Calcitriol) in Patients With Myelodysplastic Syndrome (MDS)

Start date: November 2002
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of DN-101 (calcitriol) in patients with myelodysplastic syndrome who are dependent on repeat blood transfusions.

NCT ID: NCT00048958 Active, not recruiting - Multiple Myeloma Clinical Trials

Cytogenetic Studies in Acute Leukemia and Multiple Myeloma

Start date: June 1984
Phase:
Study type: Observational

Chromosomal analysis or the study of genetic differences in patients previously untreated with AML, ALL, MDS or MM may be helpful in the diagnosis and classification of disease. It may also improve the ability to predict the course of disease and the selection of therapy. Institutions must have either an Alliance-approved cytogeneticist or an agreement from an Alliance-approved main member cytogenetics laboratory to enroll a patient on CALGB 8461. The Alliance Approved Institutional Cytogeneticists list is posted on the Alliance for Clinical Trials in Oncology website.